Dexamethasone Ocular Hypertension in the Clinically Normal Eye

Dexamethasone Implant in Pseudophakic and Nonglaucomatous Subgroup of Diabetic Macular Edema Patients: A Real Life Experience

“…The authors reported that none of the eyes showed an IOP ≥25 mm Hg or an increase in IOP by ≥10 mm Hg at 15 minutes, day 7, or month 4 after IDI injection; however, 8.6% of the eyes showed an IOP ≥25 mm Hg or an increase in IOP by ≥10 mm Hg at month 1 and 25% at month 2 (23). The IOP changes observed in our study population were similar to those reported by Armaly et al (22). An IOP of >31 mm Hg was reported to be 4% in the mentioned study (22), and in our study this rate was 2%.…”

“…The IOP changes observed in our study population were similar to those reported by Armaly et al (22). An IOP of >31 mm Hg was reported to be 4% in the mentioned study (22), and in our study this rate was 2%. Also in our series, 14% of eyes showed an increase in IOP of ≥10 mm Hg and only 2 of them (4%) needed chronic antiglaucoma medication.…”

“…An IOP of >31 mm Hg was reported to be 24% among the glaucoma suspects and only 4% in healthy volunteers. The rate of steroid glaucoma in a random population was reported to be around 30% to 40% after topical dexamethasone use in previous studies (22). Interestingly, the MEAD study showed similar results to these early studies in regard to IOP changes (18).…”

Clobetasol propionate 0.05% under occlusion for alopecia areata: Clinical effect and influence on intraocular pressure

“…In the current study, percutaneously absorbed corticosteroids appears to have had little effect on the eyes. However, care should be paid to steroid responders, as theroretically they may have a higher risk of increase in intraocular pressure caused by steroids 9 . This effect is more pronounced in children and young people, but the change is usually reversible.…”

Development of Open-Angle Glaucoma in Adults With Seropositive Rheumatoid Arthritis in Korea

“…Furthermore, subgroup analysis was performed according to 3 follow-up time frames (0-24, 0-48, and ≥49 months), age group, and sex. To exclude the use of corticosteroids as a potential confounder, a sensitivity analysis excluding corticosteroid users was performed, and to assess potential residual confounding such as frequent eye examinations in patients with RA, we also evaluated the risk of conjunctival and eyelid disorders during the follow-up period as negative control outcomes (eAppendix in the Supplement). A 2–sided P < .05 was considered significant.…”